Inactive Instrument

Amryt Pharma plc

Equities

AMYT

US03217L1061

Pharmaceuticals

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Amryt Pharma plc(NasdaqGS:AMYT) dropped from S&P Global BMI Index CI
Amryt Pharma plc(NasdaqGS:AMYT) dropped from NASDAQ Composite Index CI
Chiesi Farmaceutici S.p.A. completed the acquisition of Amryt Pharma plc from Athyrium Capital Management, LP, Highbridge Capital Management, LLC, Joe Wiley, Rory Nealon, Ray Stafford and others. CI
Amryt Pharma's Shareholders Approve Acquisition by Chiesi Farmaceutici MT
Amryt Pharma plc’s Equity Buyback announced on March 9, 2022, has expired. CI
HC Wainwright Downgrades Amryt Pharma to Neutral From Buy, Cuts Price Target to $14.50 From $18 MT
Maxim Group Downgrades Amryt Pharma to Hold From Buy MT
Cantor Fitzgerald Downgrades Amryt Pharma to Neutral From Overweight, Adjusts Price Target to $14.75 From $25 MT
Canaccord Genuity Downgrades Amryt Pharma to Hold From Buy, Adjusts Price Target to $17 From $19 MT
Sector Update: Health Care Stocks Largely Struggle Monday MT
Top Midday Gainers MT
Sector Update: Health Care Stocks Struggling to Begin New Week MT
Sector Update: Health Care MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday MT
Rate Hike Clues, China Border Reopening Fuel Gains for US Equity Futures MT
Top Premarket Gainers MT
Amryt Pharma to be Acquired by Chiesi Farmaceutici MT
Italy's Chiesi Farmaceutici to Buy Rare Disease-focused Amryt Pharma for $1.5 Billion MT
Chiesi Farmaceutici S.p.A. entered into a definitive agreement to acquire Amryt Pharma plc from Athyrium Capital Management, LP, Highbridge Capital Management, LLC, Joe Wiley, Rory Nealon, Ray Stafford and others for $1.1 billion. CI
Amryt Pharma Says Phase 3 Trial of Cholesterol Disorder Treatment Met Primary Endpoint; Shares Gain Pre-Bell MT
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH CI
Amryt Says European Medicines Agency Committee Adopts Positive Opinion on Orphan Designation for Mycapssa MT
Amryt Pharma Receives Approval for Mycapssa in Europe MT
Amryt Announces European Commission Approves Mycapssa® for the Treatment of Acromegaly CI
Amryt Pharma Says It Received New US Patent for Mycapssa MT
Chart Amryt Pharma plc
More charts
Amryt Pharma plc is a commercial-stage biopharmaceutical company. It is focused on acquiring, developing, and commercializing novel treatments for rare diseases. Its commercial business comprises three orphan disease products, such as metreleptin (Myalept/ Myalepta); lomitapide (Juxtapid/ Lojuxta), and oral octreotide (Mycapssa). Myalept is approved in the United States as an adjunct to diet as replacement therapy to treat leptin deficiency in patients with congenital or acquired generalised lipodystrophy (GL). Juxtapid is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder, homozygous familial hypercholesterolaemia (HoFH). Mycapssa is a combination of octreotide acetate and excipients, collectively called Transient Permeability Enhancer (TPE). Its development candidate, Oleogel-S10 (Filsuvez) is a treatment for the cutaneous manifestations of junctional and dystrophic (JEB and DEB) epidermolysis bullosa.
More about the company
  1. Stock
  2. Equities
  3. Stock Amryt Pharma plc - Nasdaq
  4. News Amryt Pharma plc
  5. Amryt Pharma Says European Medicines Agency Will Consult Expert Group For Review of Genetic Skin Disorder Treatment